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Summary
An alemtuzumab-based experimental immunosuppressive treatment (IST)
regimen was investigated in 35 patients with severe aplastic anaemia (SAA),
pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total
dose was 73–103 mg s.c., followed by cyclosporine. No serious toxicity due to
the regimen was observed. Adverse events were clinically irrelevant; infectious
events were rare. The total response rate was 58%, 84% and 100% in SAA,
PRCA and PWCA, respectively, with corresponding 6 months cumulative
response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is
a feasible and sufficiently safe IST regimen for patients suffering from
immune-mediated marrow failures.
Keywords: alemtuzumab, aplastic anaemia, pure red cell aplasia, pure white
cell aplasia, bone marrow failure.
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Immunosuppressive therapy (IST) is a standard treatment
for acquired aplastic anaemia (AA) (Risitano et al, 2004) and
other immune-mediated bone marrow failure syndromes
(BMFS) characterised by defective production of a single
lineage (i.e., pure red cell aplasia [PRCA], white cell aplasia
[PWCA]). The current IST regimen for AA is antithymocyte
globulin (ATG) with cyclosporine A (CyA) (Frickhofen et al,
2003; Rosenfeld et al, 2003; Maciejewski & Risitano, 2005),
while in PRCA and PWCA, IST is usually less intensive. The
major limitations associated with current IST regimens are the
side effects (especially with ATG), as well as primary treatment
failures or relapse requiring re-treatment or chronic IST
(Frickhofen et al, 2003; Maciejewski & Risitano, 2005). A
regimen retaining a marked immunosuppressive effect but
with fewer side effects and ease of administration would be
ideal. Alemtuzumab is a humanised monoclonal antibody that
specifically kills CD52-bearing cells via both antibody-depen-
dent cellular cytotoxicity and complement-mediated lysis.
Hence, alemtuzumab is a perfect candidate for testing as IST in
autoimmune diseases.
Here we report a preliminary experience with alemtuzumab
for the treatment of AA, PRCA and PWCA. The study
included a phase II prospective trial and cases collected
retrospectively as reported to the Working Party for Severe




This observational study included a total of 35 patients
reported from EBMT centres (Table I). Twenty-five patients
(11 severe aplastic anaemia [SAA], 12 PRCA and 2 PWCA)
were enrolled in a prospective clinical trial conducted in
Naples, approved by the local Institutional Review Board
(IRB); among these, 15 (6 SAA, 8 PRCA and 1 PWCA) were
untreated. Ten patients (8 SAA, 1 PRCA and 1 PWCA) were
treated in other EBMT SAA Working Party centres according
to the protocol, as recommended salvage IST; retrospective
data were collected through an EBMT survey, complying with
local IRB guidelines (Table I).
Prospective clinical trial
The pilot clinical trial (NCT00895739) was a phase II study for
SAA patients failing first-line IST, subsequently amended to
include single-lineage bone marrow failure patients, and first-
line treatment was also permitted. Alemtuzumab was admin-
istered subcutaneously in a single course over 4 or 5
consecutive days at escalating dose of 3-10-30-30-(30) mg.
Premedication included intravenous steroids, anti-histamines
and oral paracetamol. The total dose was 103 mg for SAA
patients, and 73 mg for AA/paroxysmal nocturnal haemoglo-
binuria (PNH) and PRCA/PWCA (and in two elderly SAA
patients, Table I). Re-treatment by alemtuzumab (as complete
courses or single dose) was allowed for relapse in responding
patients. Low dose (1 mg/kg) oral cyclosporine A commenced
from day 7, and then adjusted according to blood level
(targeting 100–200 ng/ml using a monoclonal assay) at the
time of immune reconstitution. An intensive anti-infectious
prophylaxis was used (Table I, Risitano et al, 2009), which
included anti-cytomegalovirus (CMV) prophylaxis by oral
vanganciclovir and weekly monitoring of CMV viraemia, anti-
Pneumocystis Jirovecii prophylaxis by oral trimethoprim-
sulphametoxazole, anti-bacterial and anti-fungal prophylaxis
in case of severe neutropenia (<0Æ5 · 109/l), and prophylactic
lamivudine in patients with possible occult hepatitis B virus
(HBV).
Response definition
Responses in SAA patients were classified according to
established criteria (Camitta, 2000), as described in Table I.
Cumulative incidences of survival and response were run using
a Kaplan–Meier method.
Results and discussion
All 25 patients enrolled in the prospective trial completed the
scheduled treatment without serious adverse events (AE).
Including additional doses given for relapse, a total of 63
courses of alemtuzumab were administered. Treatment was
administered on an outpatient basis, with the exception of
patients requiring hospitalisation for clinical reasons (e.g.
symptomatic thrombocytopenia). The most frequent AE was
injection-related fever and/or cutaneous rash, which occurred
in seven patients (28%, Table I), but they were usually mild.
Even for patients already pancytopenic before treatment,
transient worsening of blood counts [especially neutropenia,
as already reported (Gibbs et al, 2005)] was observed in 10
cases (40%), 2–6 weeks after treatment. This was treated with
G-CSF. Other AEs were increase of liver enzymes in four
patients and serum uric acid in two, which were transient in all
cases. No emergence of PNH clones was recorded. With a
median follow up of 17 months, there were six deaths, all but
one (a cardiac complication occurring in concomitance with
an infectious event) considered independent of the treatment.
Three deaths were due to pretreatment non-haematological
comorbidities, one to additional therapy employed (stem cell
transplantation), one to the underlying haematological disease
(which were reclassified as myelodysplastic syndrome with
erythroid hypoplasia); all causes of death are described in
detail in Table I.
The major concerns regarding the safety of alemtuzumab
include its associated infectious risk (Elter et al, 2009). With a
median follow up of 17 months (cumulative 433 patient-
months, including repetitive treatment in relapsing patients),
infectious events were infrequent (Table I): six cases of pyrexia
of unknown origin (PUO), one associated with fatal cardiac
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complication, and eight viral infections (one Varicella-Zoster
virus [VSV] with shingles, two Herpes Simplex virus [HSV]
and five flu) were reported, all resolving quickly. All VZV and
HSV episodes occurred after valganciclovir discontinuation.
No CMV disease, Epstein–Barr virus-related disease or lym-
phoproliferative disorders were observed. A sensitive polymer-
ase chain reaction method confirmed negative CMV viraemia
in all patients receiving prophylactic valganciclovir (Risitano
et al, 2009); four patients developed asymptomatic CMV
reactivation after the discontinuation of anti-viral prophylaxis,
but viraemia (just above the detection limit) promptly
disappeared with pre-emptive valganciclovir. Finally, one
patient with pre-treatment occult HBV infection developed
HBV reactivation (positive for Hepatitis B surface antigen and
HBV viremia) without laboratory signs of hepatitis; lamivu-
dine therapy was started and was effective in viral clearing. The
other three patients with possible occult HBV infection
received prophylactic lamivudine. This acceptable safety profile
was confirmed in the 10 additional patients receiving ale-
mtuzumab as salvage IST at other EBMT centres. Even in
heavily pretreated patients (all had received one or two ATG
courses), alemtuzumab treatment did not result in any specific
toxicity. There was one fatal sepsis (9 months after treatment,
in a non-responding patient), one CMV reactivation (in a
patient receiving famaciclovir instead of valganciclovir), one
HSV infection and one post-transplant lymphoproliferative
disorder (PTLD; this patient had received a previous transplant
and was treated with alemtuzumab after a primary graft
failure).
Alemtuzumab led to complete lympho-ablation in all
patients, with the lymphocyte count (which was normal or
almost normal in all patients) falling close to 0 · 109/l within
2–3 d, and remaining markedly reduced for several months
(especially for the CD4 subset). Within the prospective trial,
there were 5 complete responses (CR) and 3 partial responses
(PR) in the 11 SAA patients, and 8 CR and 2 PR in the 12
PRCA. Both PWCA patients achieved a CR. Among SAA
patients receiving alemtuzumab as first IST, there were three
CR and one PR (the two non-responders had a follow up of 1
and 3 months). In the EBMT survey, three of eight SAA
patients (all heavily pretreated) achieved a PR, while both of
the two PRCA and PWCA patients achieved a CR. When
combined with the data from the prospective clinical trial, the
total response rate was 58% in SAA, 84% in PRCA and 100%
in PWCA. Responses were faster in PRCA and PWCA patients
(range 1–4 months), compared with SAA (3–10 months).
Survival and cumulative incidence of response analyses in the
25 patients in the prospective trial (Fig 1) were 73% and 89%
respectively. Despite most patients receiving chronic low dose
cyclosporine A (only four patients had to discontinue the drug
due to intolerance), relapses were frequent and appeared
earlier than observed after ATG (Frickhofen et al, 2003),
irrespective of persistent lymphocytopenia; this was possibly
related to the low dose of cyclosporine A utilised in the study.
Relapse occurred in five of seven SAA and AA/PNH patients,
five of eight PRCA and one of two PWCA patients.
Alemtuzumab (administered as either single 30 mg injection
or complete courses) was still effective even in patients
experiencing multiple relapses (Table I), demonstrating easi-
ness of re-treatment. In some patients, recurrent disease led to
periodical (every 3–4 months) 30 mg injections, which worked
as maintenance treatment to prevent further relapses.
Alemtuzumab has been reported to be effective in anecdotal
cases (Killick et al, 1997; Alvares et al, 2004; Au et al, 2005;
Schu¨tzinger et al, 2005) or small series (Willis et al, 2001;
Go´mez-Almaguer et al, 2009; Kim et al, 2009). Here we report
the largest experience to date using alemtuzumab in SAA, PRCA
and PWCA. In comparison to standard ATG, alemtuzumab was
cheaper, simpler to administer (even without hospitalisation),
and injection-related side effects were negligible. Safety con-
cerns were assuaged given the low rate of infectious complica-
tions and acceptable toxicity profile, allowing its use even in
diseases with a mild clinical course (i.e., PRCA and PWCA).
Preliminary results on efficacy suggest response rates that were
Overall survival
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Fig 1. Overall survival and cumulative incidence of response of
patients included in the prospective trial. (A) Overall survival in the
whole population: with a median follow up of 17 months, the survival
at 2 years was 73%. (B) Cumulative incidence of response according to
the underlying disease: 84% in SAA, 84% in PRCA and 100% in
PWCA.
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not inferior to standard IST regimens, even if relapses were not
infrequent. However, re-treatment for relapse was easy and
effective. We provide evidence that alemtuzumab-based IST is
feasible and manageable in patients suffering from immune-
mediated BMFS, paving the way for systematic investigation in
comparison to standard IS regimens.
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